Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $9.7 million.

  • Puma Biotechnology's Free Cash Flow fell 12.20% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 27.32%. This contributed to the annual value of $38.9 million for FY2024, which is 44.64% up from last year.
  • Per Puma Biotechnology's latest filing, its Free Cash Flow stood at $9.7 million for Q3 2025, which was down 31.23% from $14.1 million recorded in Q2 2025.
  • Puma Biotechnology's Free Cash Flow's 5-year high stood at $15.7 million during Q1 2021, with a 5-year trough of -$26.9 million in Q1 2022.
  • In the last 3 years, Puma Biotechnology's Free Cash Flow had a median value of $10.4 million in 2023 and averaged $8.5 million.
  • In the last 5 years, Puma Biotechnology's Free Cash Flow slumped by 18,648.65% in 2022 and then spiked by 1,297.02% in 2025.
  • Over the past 5 years, Puma Biotechnology's Free Cash Flow (Quarterly) stood at -$5.4 million in 2021, then surged by 370.16% to $14.7 million in 2022, then dropped by 29.10% to $10.4 million in 2023, then surged by 49.77% to $15.6 million in 2024, then declined by 12.20% to $9.7 million in 2025.
  • Its Free Cash Flow was $9.7 million in Q3 2025, compared to $14.1 million in Q2 2025 and $3.6 million in Q1 2025.